Ki-67及VEGF在甲状腺乳头状癌中的表达及其临床病理学意义
|
摘要
目的研究甲状腺乳头状癌组织中增殖细胞核抗原(proliferating cell nuclear antigen, PCNA) Ki-67、血管内皮生长因子(vascular endothelial growth factor,VEGF)在甲状腺乳头状癌中的表达,及其与临床病理特征的关系。方法采用回顾性病例对照研究,选取在深圳大学第一附属医院手术治疗的139例甲状腺乳头状癌患者的石蜡病理切片,分别对癌组织和癌旁组织进行Ki-67及VEGF的免疫组化染色,并分析其与临床病理特征之间的关系。结果癌组织中Ki-67及VEGF阳性表达率分别为74.82%和78.42%,高于癌旁组织的0和13.67%,差异具有统计学意义(P=0.000)。Ki-67、VEGF的表达与甲状腺乳头状癌患者的年龄、性别、肿瘤大小无显著相关(P>0.05),但与TNM分期及有无淋巴结转移有关,在TNM分期高的和有淋巴结转移的病例中Ki-67和VEGF阳性表达率均较高(P<0.05)。Ki-67及VEGF共同表达率达77.98%,两者明显相关(P<0.05)。结论甲状腺乳头状癌组织中Ki-67及VEGF阳性表达率高,与癌旁组织比较有明显差异,与甲状腺乳头状癌的生物学行为密切相关。
Objective To study the expression of proliferating cell nuclear antigen(PCNA) Ki-67 and vascular endothelial growth factor(VEGF) in papillary thyroid carcinoma and their relationship with clinicopathological characteristics. Methods A retrospective case-control study was conducted. 139 cases of thyroid papillary carcinoma treated surgically in the First Affiliated Hospital of Shenzhen University were selected for paraffin-embedded pathological sections. Ki-67 and vascular endothelial growth factor immunohistochemical staining were performed on the cancer tissues and adjacent tissues respectively, and the relationship between the indicators and clinicopathological characteristics was analyzed. Results The positive rates of Ki-67 and VEGF in cancer tissues were 74.82% and 78.42% respectively, which were higher than that of adjacent tissues(0 and 13.67%, P=0.000). The expression of Ki-67 and VEGF was not significantly correlated with age, gender and size of thyroid papillary carcinoma(P>0.05), but was correlated with TNM stage and lymph node metastasis(P<0.05). The positive expression rates of Ki-67 and VEGF were higher in high TNM stage and lymph node metastasis patients( P<0.05). The co-expression rate of Ki-67 and VEGF was 77.98% with a significant correlation( P< 0.05). Conclusion Ki-67 and vascular endothelial growth factor are highly expressed in papillary thyroid cancer tissues,which are significantly different from the adjacent tissues and closely related to the biological behavior of papillary thyroid cancer.
Objective To study the expression of proliferating cell nuclear antigen(PCNA) Ki-67 and vascular endothelial growth factor(VEGF) in papillary thyroid carcinoma and their relationship with clinicopathological characteristics. Methods A retrospective case-control study was conducted. 139 cases of thyroid papillary carcinoma treated surgically in the First Affiliated Hospital of Shenzhen University were selected for paraffin-embedded pathological sections. Ki-67 and vascular endothelial growth factor immunohistochemical staining were performed on the cancer tissues and adjacent tissues respectively, and the relationship between the indicators and clinicopathological characteristics was analyzed. Results The positive rates of Ki-67 and VEGF in cancer tissues were 74.82% and 78.42% respectively, which were higher than that of adjacent tissues(0 and 13.67%, P=0.000). The expression of Ki-67 and VEGF was not significantly correlated with age, gender and size of thyroid papillary carcinoma(P>0.05), but was correlated with TNM stage and lymph node metastasis(P<0.05). The positive expression rates of Ki-67 and VEGF were higher in high TNM stage and lymph node metastasis patients( P<0.05). The co-expression rate of Ki-67 and VEGF was 77.98% with a significant correlation( P< 0.05). Conclusion Ki-67 and vascular endothelial growth factor are highly expressed in papillary thyroid cancer tissues,which are significantly different from the adjacent tissues and closely related to the biological behavior of papillary thyroid cancer.
引文
[1] 王先明,吴恢升,王敏,等.分化型甲状腺癌的风险评估和个体化治疗策略[J].医学与哲学,2012,30(10):9-13.
[2] 吴恢升,何劲松,陈伟财,等.选择性颈淋巴结清除术在乳头状甲状腺癌手术治疗的临床应用[J].中国普通外科杂志,2012,21(5):532-535.
[3] Atamari-Anahui N,Morales-Concha L,Moncada-Arias AG,et al.National trends in prevalence and mortality rates of thyroid cancer using data from the Ministry of Health of Peru[J].Medwave,.2019,19(4):e7631.
[4] Farahati J,M?der U,Gilman E,et al.Changing trends of incidence and prognosis of thyroid carcinoma[J].Nuklearmedizin,2019 ,58(2):86-92.
[5] Kim WB.A closer look at papillary thyroid carcinoma[J].Endocrinol Metab (Seoul),2015,30(1):1-6.
[6] Krook KA,Fedewa SA,Chen AY.Prognostic indicators in well-differentiated thyroid carcinoma when controlling for stage and treatment[J].Laryngoscope,2015,125(4):1021-1027.
[7] Park JY,Kim DW,Park HK,et al.Comparison of T stage,N stage,multifocality,and bilaterality in papillary thyroid carcinoma patients according to the presence of coexisting lymphocytic thyroiditis[J].Endocr Res,2015,40(3):151-155.
[8] Girardi FM,Barra MB,Zettler CG.Predictive factors for lymph node metastasis in solitary papillary thyroid carcinomas:a retrospective study[J].Pathol Oncol Res,2015,21(1):59-64.
[9] Kim HJ,Park HK,Byun DW,et al.Number of tumor foci as predictor of lateral lymph node metastasis in papillary thyroid carcinoma[J].Head Neck,2015 ,37(5):650-654.
[10] Park CW,Song JW,Chun BK,et al.Factors associated with metastatic lymph node ratio,extranodal extension in the central compartment code-positive papillary thyroid carcinoma[J].Head and Neck,2015.2015,58(7):475-480.
[11] 蒋圣早,成启明.CXCR4和Ki67表达与甲状腺癌预后的相关性研究[J].中国现代普通外科进展,2017,20 (1) :73-75.
[12] 尚培中,张进权,柳勇,等.VEGF和Gal-3表达与甲状腺乳头状癌浸润转移的关系[J].中国现代普通外科进展,2017,20(6):488-489,492.
[13] 程江明,柴虎林.KAI1与ki-67在甲状腺癌中的研究进展[J].系统医学,2018,3(7)185-187.
[14] Tang J,Gui C,Qiu S,et al.The clinicopathological significance of Ki67 in papillary thyroid carcinoma:a suitable indicator?[J].World J Surg Oncol,2018 May 31;16(1):100.doi:10.1186/s12957-018-1384-8.
[15] Skuletic V,Radosavljevic GD,Pantic J,et al.Angiogenic and lymphangiogenic profiles in histological variants of papillary thyroid carcinoma[J].Pol Arch Intern Med,2017,127(6):429-437.
[2] 吴恢升,何劲松,陈伟财,等.选择性颈淋巴结清除术在乳头状甲状腺癌手术治疗的临床应用[J].中国普通外科杂志,2012,21(5):532-535.
[3] Atamari-Anahui N,Morales-Concha L,Moncada-Arias AG,et al.National trends in prevalence and mortality rates of thyroid cancer using data from the Ministry of Health of Peru[J].Medwave,.2019,19(4):e7631.
[4] Farahati J,M?der U,Gilman E,et al.Changing trends of incidence and prognosis of thyroid carcinoma[J].Nuklearmedizin,2019 ,58(2):86-92.
[5] Kim WB.A closer look at papillary thyroid carcinoma[J].Endocrinol Metab (Seoul),2015,30(1):1-6.
[6] Krook KA,Fedewa SA,Chen AY.Prognostic indicators in well-differentiated thyroid carcinoma when controlling for stage and treatment[J].Laryngoscope,2015,125(4):1021-1027.
[7] Park JY,Kim DW,Park HK,et al.Comparison of T stage,N stage,multifocality,and bilaterality in papillary thyroid carcinoma patients according to the presence of coexisting lymphocytic thyroiditis[J].Endocr Res,2015,40(3):151-155.
[8] Girardi FM,Barra MB,Zettler CG.Predictive factors for lymph node metastasis in solitary papillary thyroid carcinomas:a retrospective study[J].Pathol Oncol Res,2015,21(1):59-64.
[9] Kim HJ,Park HK,Byun DW,et al.Number of tumor foci as predictor of lateral lymph node metastasis in papillary thyroid carcinoma[J].Head Neck,2015 ,37(5):650-654.
[10] Park CW,Song JW,Chun BK,et al.Factors associated with metastatic lymph node ratio,extranodal extension in the central compartment code-positive papillary thyroid carcinoma[J].Head and Neck,2015.2015,58(7):475-480.
[11] 蒋圣早,成启明.CXCR4和Ki67表达与甲状腺癌预后的相关性研究[J].中国现代普通外科进展,2017,20 (1) :73-75.
[12] 尚培中,张进权,柳勇,等.VEGF和Gal-3表达与甲状腺乳头状癌浸润转移的关系[J].中国现代普通外科进展,2017,20(6):488-489,492.
[13] 程江明,柴虎林.KAI1与ki-67在甲状腺癌中的研究进展[J].系统医学,2018,3(7)185-187.
[14] Tang J,Gui C,Qiu S,et al.The clinicopathological significance of Ki67 in papillary thyroid carcinoma:a suitable indicator?[J].World J Surg Oncol,2018 May 31;16(1):100.doi:10.1186/s12957-018-1384-8.
[15] Skuletic V,Radosavljevic GD,Pantic J,et al.Angiogenic and lymphangiogenic profiles in histological variants of papillary thyroid carcinoma[J].Pol Arch Intern Med,2017,127(6):429-437.